search

menu

  • Research Research
    • Where science meets inspired minds

    • Back
    • Research
    • Our Science
    • Research Groups
    • Facilities & Platforms
    • Clinical research
    • Find a researcher
    • Publications
    • Knowledge Transfer
  • Careers & study Careers & study
    • Become a leader in cancer research

    • Back
    • Careers & study
    • Vacancies
    • Faculty
    • Scientific staff
    • Scientific support staff
    • Postdoctoral fellows
    • PhD Students
    • Operational staff
    • Clinical fellows
    • Life in Amsterdam
    • Student internships
  • News & Events News & Events
    • Check out our stories and events

    • Back
    • News & Events
    • News
    • Media & Press
    • Calendar
  • About us About us
    • Maximum impact for cancer patients

    • Back
    • About us
    • Our vision
    • Organization
    • Collaborations
    • Responsible Research
    • Support us
    • Visit us
    • Contact us
  • Support us
Support us
  • Home
  • Our Research
  • Research
  • Research Groups
  • Olga Husson
  • Our Research
  • Rare Cancers & Sarcoma

Rare Cancers & Sarcoma

Rare cancers, defined as those with an incidence of fewer than six cases per 100,000 people per year, account for approximately 24% of all cancer diagnoses [1,2]. They are known to be extremely heterogeneous and appear in different parts of the body. This diversity, combined with their rarity, means many patients are managed outside specialised centres, contributing to delays and variability in care. Despite their collective impact, rare cancers often receive less research attention than more common malignancies, leaving patients with limited treatment guidelines, fewer clinical trials, and geographical disparities in expertise [5].

Among rare cancers, sarcomas represent only 1% of adult tumours, with 4-5 cases per 100,000 people per year in Europe [1,3,4]. Sarcomas are a heterogeneous group of over 70 histological subtypes arising in bone and soft tissue, which complicates accurate diagnosis and standardised treatment.

Health-related quality of life (HRQoL) is a crucial aspect of cancer care, yet research on HRQoL in rare solid cancers and sarcomas remains limited. Given the unique challenges these patients face—late diagnosis, limited treatment options, and small, dispersed populations—understanding their HRQoL is essential for improving care and support strategies. Our research addresses this gap by evaluating how HRQoL is assessed in these populations, developing more tailored measurement approaches, and investigating challenges in their diagnostic trajectories.

Throughout this work, we collaborate closely with the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group to ensure robust methodologies and meaningful patient-centred outcomes.

 

References

  1. Weidema, M.E., et al., Health-related quality of life and symptom burden of epithelioid hemangioendothelioma patients: a global patient-driven Facebook study in a very rare malignancy. Acta Oncol, 2020. 59(8): p. 975-982. 

  2. Franzoi, I.G., et al., The psychological impact of sarcoma on affected patients. Psychooncology, 2023. 32(12): p. 1787-1797. 

  3. Stiller, C.A., et al., Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer, 2013. 49(3): p. 684-95. 

  4. Holthuis, E.I., et al., Improving Diagnosis and Care for Patients With Sarcoma: Do Real-World General Practitioners Data and Prospective Data Collections Have a Place Next to Clinical Trials? JCO Clin Cancer Inform, 2024. 8: p. e2400054. 

  5. Padilla, C.S., et al., Health-Related Quality of Life (HRQoL) Assessments in Research on Patients with Adult Rare Solid Cancers: A State-of-the-Art Review. Cancers (Basel), 2025. 17(3). 

Where science meets inspired minds

Contact

Plesmanlaan 121
1066CX Amsterdam

020 512 9111 communicatie@nki.nl

Quick links

  • Vacancies
  • News
  • Contact us
  • Media & Press

Follow us on

Disclaimer
Privacy statement
Cookies
Change cookie settings

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.